RxDoctor Payments Data

Amin Sabet, MD

Cardiovascular Disease · Fresno, CANPI 1801258587

Payments from drug & device makers

$57,013in general payments, 2019–2025

Across 97 payments — averaging $587.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Kiniksa Pharmaceuticals International, PLC$36K
  • Agepha Pharma FZ LLC$9K
  • Pfizer$7K
  • Sobi, Inc$3K
  • Verona Pharma, Inc.$843
  • Amgen$618
  • plus $892 from 13 others

What the payments were for

  • Consulting fees$12,88623%
  • Speaking & faculty fees$30,45054%
  • Travel & lodging$8,66115%
  • Food & beverage$4,1097%
  • Education$650%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$57,013 in reported general payments places this provider in the 85th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$162,687
Medicare patients
1,501
Services billed
2,834

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban52$54,797
EntrestoSacubitril/Valsartan18$16,518
JardianceEmpagliflozin27$15,950
Repatha SyringeEvolocumab13$7,045
Rosuvastatin Calcium77$967
Losartan Potassium93$706
Metoprolol Succinate60$698
Atorvastatin Calcium97$698
Nifedipine ErNifedipine14$492
Amlodipine Besylate69$422
Metoprolol Tartrate41$341
Ezetimibe19$339
Carvedilol40$308
Furosemide24$180
Nitroglycerin16$131

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$6,642$54,79752 claims
NovartisEntresto$102$16,51818 claims
Boehringer IngelheimJardiance$111$15,95027 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Fresno

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →